Heart diseases are a very important issue nowadays as medical experts and researchers are permanently looking into how to reduce their numbers significantly. Bayer is one of the many groups who has given heart diseases a great deal of interest and it seems that all this interest has finally paid off. Bayer is pushing its newest heart-failure drug into its final stage tests based on previous success.
The new drug was deemed more successful than its competitors in mid-stage trial. Thus, Bayer is looking forward to putting it out on the market for all the people whose hearts are in danger, hoping that they might increase life expectancy and life quality. And it would not be the first daring dream that the group ever pursued. The launch of Eylea and Xarelto are further proof of the group’s capacity.
The new drug that we are talking about is finerenone. It is a drug that is quite far from reaching the pharmacies’ shelves and it is an improved version of drugs better known as mineralocorticoid receptor antagonists (MRAs). The current MRAs, spironolactone and eplerenone, are widely known by the name Inspra and they are branded by Pfizer.
These MRAs are not exactly safe for a large number of patients because they cause a dangerous increase of potassium within the blood. This means that patients can either experience irregular heartbeats and might even go into cardiac arrest. Quite a paradox: a hear medicine that can stop your heart. They are also notorious for causing some kidney issues.
But Bayer’s drug seems to work differently, casually dodging all of these issues and ensuring that the heart is properly treated. Researchers have taken great interest into the pill, thus they will be watching its development to ensure that no issues will arise during its testing phase.
The vice president of the American College of Cardiology, Mary Norine Walsh, also expressed her enthusiasm when speaking about the new pill, indicating that eliminating high potassium levels would bring “a huge benefit to the patients”.
The second phase of the drug trial led to some interesting developments: the use of finerenone has led to fewer deaths and fewer hospital admissions for those who participated in the first phase of the trial. The group was compared to another control group which had been using eplerenone during the same testing phase.
While the confirmation of this new pill would not only add to Bayer’s success, it would also mean that people around the world who have heart issues could be able to live free of one more worry in the following years.
Photo Credits wikimedia.org